Objective: To explore the impact of a nurse-led chronic disease management model on the quality of care and satisfaction of maintenance hemodialysis patients. Methods: 72 patients who received maintenance hemodialysis (MHD) from June 2021 to March 2022 were selected to undergo the nurse-led chronic disease management model. The hemodialysis indexes, nutritional status, and the occurrence of adverse events were assessed after 24 weeks of the intervention, and patients’ satisfaction was investigated and analyzed. Results: Comparing pre-intervention and after 24 weeks of intervention, urea reduction rate and urea clearance were improved but not statistically different (P > 0.05), but β2-microglobulin was significantly reduced compared with pre-intervention (P < 0.05); after 24 weeks of intervention, the effect of decreasing blood calcium, parathyroid hormone, and potassium levels was not obvious (P > 0.05), and the level of blood phosphorus decreased significantly compared with pre-intervention (P < 0.01), albumin and hemoglobin levels were increased and better than before intervention (P < 0.05); after 24 weeks of intervention, the incidence of intradialytic hypotension and hypertension was lower than before intervention (P < 0.05), and the total incidence of complications was significantly lower than before intervention (P < 0.01); there was no significant difference in the Self-Depression Scale scores after 24 weeks of intervention (P > 0.05), and Self-Anxiety Scale scores were significantly lower and better than before intervention (P < 0.01). Patient satisfaction was greatly improved, with a statistically significant difference (P < 0.05). Conclusion: The chronic disease management intervention model led by specialized nurses is conducive to improving the psychological state and nutritional status of dialysis patients, enhancing the adequacy of dialysis for patients, reducing the incidence of related complications, and ultimately achieving the purpose of improving the quality of life of patients, which has significant clinical value.